Table 1.
Clinical characteristics between high and low CDCA8 expression groups.
| Characteristics | Overall/n (%) | Frequency in low CDCA8 expression group (%) | Frequency in high CDCA8 expression group (%) | p-value* |
|---|---|---|---|---|
| Gender | 0.392 | |||
| Male | 99 (76.2) | 29 (82.9) | 70 (73.7) | |
| Female | 31 (23.8) | 6 (17.1) | 25 (26.3) | |
| Age | 0.087 | |||
| <60 years | 107 (82.3) | 25 (71.4) | 82 (86.3) | |
| ≥60 years | 23 (17.7) | 10 (28.6) | 13 (13.7) | |
| Progression | 0.147 | |||
| No progression | 70 (53.8) | 23 (65.7) | 47 (49.5) | |
| Progression | 60 (46.2) | 12 (34.3) | 48 (50.5) | |
| Tumor Stage | 0.082 | |||
| I–II | 71 (54.6) | 24 (68.6) | 47 (49.5) | |
| III–IV | 59 (45.4) | 11 (31.4) | 48 (50.5) | |
| Status | 0.535 | |||
| Alive | 109 (83.8) | 31 (88.6) | 78 (82.1) | |
| Death | 21 (16.2) | 4 (11.4) | 17 (17.9) | |
| T | 0.272 | |||
| T1–T2 | 81 (62.3) | 25 (71.4) | 56 (58.9) | |
| T3–T4 | 49 (37.7) | 10 (28.6) | 39 (41.1) | |
| M | 0.509 | |||
| M0 | 126 (96.9) | 35 (100) | 91 (95.8) | |
| M1 | 4 (3.1) | 0 (0) | 4 (4.2) | |
| N | <0.001 | |||
| N0 | 49 (37.7) | 28 (80) | 21 (22.1) | |
| N1–N3 | 81 (62.3) | 7 (20) | 74 (77.9) |
*Chi-square test, p-value < 0.05 means significantly different.